Related Experiment Video
Updated: Jun 23, 2026
08:57
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Stathmin as a marker for malignancy in pheochromocytomas
P Björklund1, K Cupisti, M Fryknäs
1Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
Summary
Stathmin (STMN1) is significantly overexpressed in malignant pheochromocytomas, offering a potential new diagnostic marker for these rare adrenal tumors. Further research is needed to confirm its diagnostic utility.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Pheochromocytomas are rare adrenal medulla tumors with a 10% malignancy rate.
- Distinguishing malignant from benign pheochromocytomas is challenging, lacking specific diagnostic markers.
- Genetic aberrations are known, but none are definitively linked to malignancy.
Purpose of the Study:
- To identify novel molecular markers for differentiating malignant pheochromocytomas.
- To investigate gene expression profiles in pheochromocytomas compared to normal adrenal medulla.
Main Methods:
- Utilized an expression microarray with 7770 cDNA clones to analyze gene expression.
- Confirmed mRNA overexpression of stathmin (STMN1) using RT-PCR.
- Validated stathmin protein overexpression via immunohistochemistry and Western blot analysis.
Main Results:
- Stathmin (STMN1) was the most conspicuously overexpressed gene in pheochromocytomas.
- mRNA levels showed 6-8 fold increase in benign/malignant tumors and 16-fold in metastases.
- Protein overexpression was confirmed, with distinct levels between benign and malignant/metastatic specimens.
Conclusions:
- Stathmin (STMN1) shows promise as a potential diagnostic marker for malignant pheochromocytomas.
- Further clinical evaluations are warranted to establish stathmin's role in diagnosis.
- This finding could improve the differential diagnosis of adrenal medulla tumors.
